Altimmune, Inc. (ALT)
2.03
-0.02
(-0.98%)
USD |
NASDAQ |
Oct 27, 14:53
Altimmune Price to Book Value : 0.8325 for Oct. 27, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 0.8407 |
| October 23, 2026 | 0.8694 |
| October 22, 2026 | 0.8899 |
| October 21, 2026 | 0.9145 |
| October 20, 2026 | 0.9432 |
| October 19, 2026 | 0.9145 |
| October 16, 2026 | 0.9022 |
| October 15, 2026 | 0.9678 |
| October 14, 2026 | 0.9473 |
| October 13, 2026 | 0.9966 |
| October 12, 2026 | 1.050 |
| October 09, 2026 | 1.070 |
| October 08, 2026 | 1.066 |
| October 07, 2026 | 1.091 |
| October 06, 2026 | 1.095 |
| October 05, 2026 | 1.095 |
| October 02, 2026 | 1.122 |
| October 01, 2026 | 1.132 |
| September 30, 2026 | 1.173 |
| September 29, 2026 | 1.218 |
| September 28, 2026 | 1.214 |
| September 25, 2026 | 1.255 |
| September 24, 2026 | 1.247 |
| September 23, 2026 | 1.308 |
| September 22, 2026 | 1.398 |
| Date | Value |
|---|---|
| September 21, 2026 | 1.341 |
| September 18, 2026 | 1.333 |
| September 17, 2026 | 1.329 |
| September 16, 2026 | 1.329 |
| September 15, 2026 | 1.325 |
| September 14, 2026 | 1.353 |
| September 11, 2026 | 1.341 |
| September 10, 2026 | 1.349 |
| September 09, 2026 | 1.374 |
| September 08, 2026 | 1.378 |
| September 04, 2026 | 1.403 |
| September 03, 2026 | 1.325 |
| September 02, 2026 | 1.345 |
| September 01, 2026 | 1.267 |
| August 31, 2026 | 1.275 |
| August 28, 2026 | 1.275 |
| August 27, 2026 | 1.329 |
| August 26, 2026 | 1.292 |
| August 25, 2026 | 1.312 |
| August 24, 2026 | 1.275 |
| August 21, 2026 | 1.275 |
| August 20, 2026 | 1.210 |
| August 19, 2026 | 1.280 |
| August 18, 2026 | 1.218 |
| August 17, 2026 | 1.230 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Protalix Biotherapeutics, Inc. | 2.849 |
| Taysha Gene Therapies, Inc. | 3.536 |
| Humacyte, Inc. | 3.984 |
| Liquidia Corp. | 20.62 |
| Agenus, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 8184.45 |
| Price | 2.03 |
| Earnings Yield | -38.86% |
| Market Cap | 394.78M |